103 related articles for article (PubMed ID: 32447421)
1. A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors.
Murray Stewart T; Desai AA; Fitzgerald ML; Marton LJ; Casero RA
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1089-1096. PubMed ID: 32447421
[TBL] [Abstract][Full Text] [Related]
2. A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Murray Stewart T; Von Hoff D; Fitzgerald M; Marton LJ; Becerra CHR; Boyd TE; Conkling PR; Garbo LE; Jotte RM; Richards DA; Smith DA; Stephenson JJ; Vogelzang NJ; Wu HH; Casero RA
Cancer Chemother Pharmacol; 2021 Jan; 87(1):135-144. PubMed ID: 33215270
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of N1-N11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies.
Streiff RR; Bender JF
Invest New Drugs; 2001; 19(1):29-39. PubMed ID: 11291831
[TBL] [Abstract][Full Text] [Related]
4. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of the polyamine analog N1,N14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors.
Wilding G; King D; Tutsch K; Pomplun M; Feierabend C; Alberti D; Arzoomanian R
Invest New Drugs; 2004 Apr; 22(2):131-8. PubMed ID: 14739661
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.
Goyal L; Supko JG; Berlin J; Blaszkowsky LS; Carpenter A; Heuman DM; Hilderbrand SL; Stuart KE; Cotler S; Senzer NN; Chan E; Berg CL; Clark JW; Hezel AF; Ryan DP; Zhu AX
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1305-14. PubMed ID: 24121453
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
11. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
de Braud F; Cascinu S; Spitaleri G; Pilz K; Clementi L; Liu D; Sikken P; De Pas T
Ann Oncol; 2015 Nov; 26(11):2341-6. PubMed ID: 26395347
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer.
Hahm HA; Ettinger DS; Bowling K; Hoker B; Chen TL; Zabelina Y; Casero RA
Clin Cancer Res; 2002 Mar; 8(3):684-90. PubMed ID: 11895896
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
[TBL] [Abstract][Full Text] [Related]
15. Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancy.
Creaven PJ; Perez R; Pendyala L; Meropol NJ; Loewen G; Levine E; Berghorn E; Raghavan D
Invest New Drugs; 1997; 15(3):227-34. PubMed ID: 9387045
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Hong DS; Bowles DW; Falchook GS; Messersmith WA; George GC; O'Bryant CL; Vo AC; Klucher K; Herbst RS; Eckhardt SG; Peterson S; Hausman DF; Kurzrock R; Jimeno A
Clin Cancer Res; 2012 Aug; 18(15):4173-82. PubMed ID: 22693357
[TBL] [Abstract][Full Text] [Related]
18. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
19. A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer.
Wolff AC; Armstrong DK; Fetting JH; Carducci MK; Riley CD; Bender JF; Casero RA; Davidson NE
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5922-8. PubMed ID: 14676116
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
